Current view from alzheimer disease to type 2 diabetes mellitus

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 533-542

  Rasool, Mahmood ^a   Malik, Arif ^b   Qazi, Aamer M ^c   Sheikh, Ishfaq A ^a   Manan, Abdul ^b   Shaheen, Sumaira ^b   Qazi, Mahmood H ^b   Chaudhary, Adeel G ^a   Abuzenadah, Adel M ^a   Asif, Muhammad ^d   Alqahtani, Mohammed H ^a   Iqbal, Zafar ^e   Shaik, Munvar M ^f   Gan, Siew H ^f   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF LAHORE   (Pakistan)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d Fundamental and Applied Biology Group King Fahd Medical Research Center King Abdulaziz University ^*  (Pakistan)

^e KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^f SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Amyloid; Neurodegenerative; Pancreatic cells; Type 2 diabetes mellitus

Indexed keywords

ACETYLCHOLINESTERASE; AMYLIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE; GLYCOGEN SYNTHASE KINASE; INSULIN RECEPTOR; INSULINASE; MESSENGER RNA; NANOPARTICLE; PRESENILIN; SOMATOMEDIN C RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; COGNITION; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MITOCHONDRIAL DYNAMICS; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET CELL; PATHOGENESIS; PATHOLOGY; PREVALENCE; RISK FACTOR; TREATMENT PLANNING; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PROTEOMICS;

ALZHEIMER DISEASE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION PROFILING; HUMANS; PROTEOMICS;

EID: 84904467676     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660167     Document Type: Article

References (109)

1. Shaik AS, Raja AE, Vijayalakshmi M, Devalarao G. Alzhemier's Disease-Pathophysiology and Treatment. Intl J Pharm Biosci 2010; 1(2): 1-11.
2. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer's disease, a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012; 1: 18.
3. Hebda JA, Saraogi I, Magzoub M, Hamilton AD, Miranker AD. A Peptidomimetic Approach to Targeting Pre-amyloidogenic States in Type II Diabetes. Chem Biol 2009; 16: 943-50.
4. Rönnemaa E, Zethelius B, Sundelöf J. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71: 1065-71.
5. Herbert LE, Weuve J, Scherr PA, Evans DA. AD in the United States (2010-2050) estimated using the 2010 Census. Neurology 2013; 80(19): 1778-83.
6. World Alzheimer Report, 2010. The Global Economic Impact of Dementia. Alzheimer's Disease International, 2010; p. 15.
7. Badran M, Laher I. Type 2 Diabetes Mellitus in Arabic-Speaking Countries. Int J Endocrin 2012; 11: 902873.
8. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia, the Rotterdam Study. Neurology 1999; 53: 1937-42.
9. Kroner Z. The relationship between Alzheimer's disease and diabetes, type 3 diabetes? Altern Med Rev 2009; 14: 373-9.
10. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferatoractivated receptor-gamma (PPARgamma) in Alzheimer's disease, therapeutic implications. CNS Drugs 2008; 22: 1-14.
11. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010; 107: 7036-41.
12. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease, link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-68.
13. Beeler N, Riederer BM, Waeber G, Abderrahmani A. Role of the JNKinteracting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull 2009; 80: 274-81.
14. Miklossy J, Qing H, Radenovic A, et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 2010; 31: 1503-15.
15. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expres-sion and signaling mechanisms in AD-is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
16. Viola KL, Velasco PT, Klein WL. Why Alzheimer's is a disease of memory, the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 2008; 12: 51-7.
17. de la Monte SM, Tong M, Lester-Coll N. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes, relevance to AD. J Alzheimers Dis 2006; 10: 89-109.
18. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of AD, implications for treatment. CNS Drugs 2003; 17: 27-45.
19. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Curr Pharm Des 2003; 9: 795-800.
20. Freychet P. Insulin receptors and insulin action in the nervous system. Diabetes Metab Res Rev 2000; 16: 390-2.
21. Bingham EM, Hopkins D, Smith D. The role of insulin in human brain glucose metabolism, an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51: 3384-90.
22. Craft S, Watson GS. Insulin and neurodegenerative disease, shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
23. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol. Cell Endocrinol 2001; 177: 125-34.
24. Werner H, Roberts, CTJ, Raizada MK, et al. Developmental regulation of the insulin and insulin-like growth factor receptors in the central nervous system. In: Receptors in the Developing Nervous System; Zagon IS, McLaughlin PJ, Eds.; London, Chapman and Hall 1993; pp. 109-27.
25. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and AD, shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
26. de la Monte SM. Insulin resistance and Alzheimers's disease. BMB Rep 2009; 42: 475-81.
27. Westerman MA, Cooper-Blacketer D, Mariash A. The relationship between Abeta and memory in the Tg2576 mouse model of AD. J Neurosci 2002; 22: 1858-67.
28. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes, a review. Brain Res Rev 2007; 56: 384-402.
29. Maiorini AF, Gaunt MJ, Jacobsen TM, et al. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases J Clin Pharm Ther 2002; 27(3): 169-83.
30. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
31. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986; 83: 4044-8.
32. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways, a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622.
33. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-71.
34. Calabrese V, Scapagnini G, Giuffrida SAM, Bates TE, Clark JB. Mitochondrial involvement in brain function and dysfunction, relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001; 26: 739-64.
35. Orth M, Schapira AH. Mitochondria and degenerative disorders. Am J Med Genet 2001; 106: 27-36.
36. De Felice FG, Wu D, Lambert MP. AD-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29: 1334-47.
37. Carlsson CM. Type 2 Diabetes Mellitus, Dyslipidemia and AD. J Alzheimer Dis 2010; 20: 711-22.
38. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. PNAS 2003; 100(7): 4162-7.
39. Miners JS, Baig S, Palmer J, et al. A beta-degrading enzymes in AD. Brain Pathol 2008; 18: 240-52.
40. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloidbeta peptide in AD, review and hypothesis. Neurobiol Aging 2006; 27: 190-8.
41. Zhao J, Li L, Leissring MA. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol Neurodegener 2009; 4: 4.
42. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset AD is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-9.
43. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008; 58: 681-93.
44. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genomewide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41.
45. Tundo GR, Sbardella D, Ciaccio C, et al. Insulin-degrading enzyme (IDE): a novel heat shock-like protein. J Biol Chem 2013; 288(4): 2281-9.
46. Nowotny P, Kwon JM, Goate AM. Alzheimer Disease. Encyclopedia of Life Sciences, Nature Publishing Group (NPG): 2001; pp. 1-6.
47. Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol 2006; 361: 932-44.
48. Martins IJ, Berger T, Sharman MJ, et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 2009; 111: 1275-308.
49. Wolfe MS. Secretase targets for AD, identification and therapeutic potential. J Med Chem 2001; 44: 2039-60.
50. Goedert M, Spillantini G. A Century of AD. Science 2006; 314: 777-81.
51. Bird TD. Early-Onset Familial Alzheimer Disease. In: Pagon RA, Adam MP, Ardinger HH, et al., Eds. Gene Reviews. University of Washington, Seatle 2007; pp. 1993-2014.
52. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for AD, a review. Brain Res Bull 2003; 61(1): 1-24.
53. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease, risk, mechanisms and therapy. Nat Rev Neurol 2013; 1-13.
54. Miyamoto Y, Chen L, Sato M, et al. Hippocampal synaptic modulation by the phosphotyrosine adapter protein AhcC/N-Shc via interaction with the NMDA receptor. J Neurosci 2005; 16: 1826-35.
55. Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 2006; 23: 3375-84.
56. Chen X, Garelick MG, Wang H, et al. PI3 kinase signaling is required for retrieval and extinction of contextual memory. Nat Neurosci 2005; 8: 925-31.
57. Chiang HC, Wang L, Xie Z, Yau A, Zhong Y. PI3 kinase signaling is involved in Aβ-induced memory loss in Drosophila. Proc Natl Acad Sci USA 2010; 107: 7060-5.
58. Wan Q, Xiong ZG, Man HY, et al. Recruitment of functional GABAA receptors to postsynaptic domains by insulin. Nature 1997; 388: 686-90.
59. Accili D, Arden KC. FOXOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-6.
60. van der Horst A, Burgering BM. Stressing the role of FOXO proteins in lifespan and disease. Nat Rev Mol. Cell Biol 2007; 8: 440-50.
61. Huang H, Tindall DJ. Dynamic FOXO transcription factors. J Cell Sci 2007; 120: 2479-87.
62. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-25.
63. Manolopoulos KN, Klotz L-O, Korsten P, Bornstein SR, Barthel A. Linking Alzheimer's disease to insulin resistance, the FOXO response to oxidative stress. Mol Psychiatry 2010; 15: 1046-52.
64. Boland B, Nixon RA. Neuronal macroautophagy, from development to degeneration. Mol Aspects Med 2006; 27(5-6): 503-19.
65. Grbovic OM, Mathews PM, Jiang Y. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem 2003; 278: 31261-8.
66. Pasternak SH, Bagshaw RD, Guiral M. Presenilin-1: nicastrin, amyloid precursor protein and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem 2003; 278: 26687-94.
67. Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in AD pathogenesis, a review. Neurochem Res 2000; 25: 1161-72.
68. Terman A, Brunk UT. Lipofuscin. Int J Biochem Cell Biol 2004; 36(8): 1400-4.
69. Terman A, Dalen H, Brunk UT. Ceroid/lipofuscin-loaded human fibroblasts show decreased survival time and diminished autophagocytosis during amino acid starvation. Exp Gerontol 1999; 34(8): 943-57.
70. Ward WF. Protein degradation in the aging organism. Prog Mol Subcell Biol 2002; 29: 35-42.
71. Tan SH, Shui G, Zhou J, et al. Induction of autophagy by palmitic acid via a PKC-mediated signalling pathway independent of mTOR. J Biol Chem 2012; 287(18): 14364-76.
72. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 2009; 52: 1083-6.
73. Kwok JBJ. Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2010; 2(5): 671-82.
74. Kandel ER. The molecular biology of memory storage, a dialogue between genes and synapses. Science 2001; 294(5544): 1030-8.
75. Graff J, Kim D, Dobbin MM, Tsai LH. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 2011; 91(2): 603-49.
76. Brownell JE, Zhou J, Ranalli T, et al. Tetrahymena histone acetyltransferase A, a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996; 84(6): 843-51.
77. Reichenberg A, Mill J, MacCabe JH. Epigenetics, genomic mutations and cognitive function. Cogn Neuropsychiatry 2009; 14: 377-90.
78. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Antuono P. AD and vascular dementia in developing countries, prevalence, management and risk factors. Lancet Neurol 2008; 7: 812-26.
79. Hakansson K, Rovio S, Helkala EL, Vilska AR, Kivipelto M. Association between mid-life marital status and cognitive function in later life, population based cohort study. Br Med J 2009; 339: 2462.
80. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet and risk of Alzheimer disease. JAMA 2009; 302: 627-37.
81. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors, basic concepts and clinical applications. Epigenetics 2006; 1: 7-13.
82. Colnot S, Niwa-Kawakita M, Hamard G, Godard C, Perret C. Colorectal cancers in a new mouse model of familial adenomatous polyposis, influence of genetic and environmental modifiers. Lab Invest 2004; 84: 1619-30.
83. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13.
84. Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008; 29: 254-64.
85. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24: 78-90.
86. Ling C, Del Guerra S, Lupi R, et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008; 51: 615-22.
87. Mariam F, Eskander NGN, Elaine YL, Bahiyyih K. Rivastigmine is a potent inhibitor of acetyl-and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005; 1060: 144-52.
88. Sanchez CG, Salceda R. Effect of streptozotocin induced diabetes on activities of cholinesterases in the rat retina. IUBMB Life 2000; 49: 283-7.
89. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G. Selective butyrylcholinsterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer's ß-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-8.
90. Chiti F, Dobson CM. Protein misfolding, functional amyloid and human disease. Annu Rev Biochem 2006; 75(1): 333-66.
91. Caughey B, Lansbury PT. Proto fibrils, pores, fibrils and neurodegeneration, separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26(1): 267-98.
92. Schnabel J. Protein folding, the dark side of proteins. Nature 2010; 464(7290): 828-9.
93. Giehm L, Svergun DI, Otzen DE, Vestergaard B. Low-resolution structure of a vesicle disrupting & α,-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci USA 2011; 108(8): 3246-51.
94. Cooper GJ, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84(23): 8628-32.
95. Chiti F, Webster P, Taddei N, et al. Designing conditions for in vitro formation of amyloid proptofilaments and fibrils. Proc Natl Acad Sci USA 1999; 96: 3590-4.
96. Fandrich M, Dobson CM. The behavior of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J 2002; 21: 5682-90.
97. Scheibel T, Parthasarathy R, Sawicki G, et al. Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition. Proc Natl Acad Sci USA 2003; 100(8): 4527-32.
98. Singh S, Bhattacharya J, Datta H, Dasgupta AK. Anti-glycation activity of gold nanoparticles. Nanomed Nanotech Biol Med 2009; 5: 21-9.
99. Seneviratne C, Narayanan R, Liu W, Dain J. The in vitro inhibition effect of 2nm gold nanoparticles on non-enzymatic glycation of human serum albumin. Biochem Biophys Res Commun 2012; 422: 447-54.
100. Kim J, Hong C, Koo Y, Choi H, Lee K. Anti-glycation effect of gold nanoparticles on collagen. Biol Pharm Bull 2012; 35: 260-4.
101. Sheikpranbabu S, Kalishwaralal K, Lee K, et al. The inhibition of advanced glycation end-products-induced retinal vascular permeability by silver nanoparticles. Biomaterials 2010; 31: 2260-71.
102. Lanctot DL, Rajaram RD, Herrmann N. Review, therapy for AD, how effective are current treatments? Ther Adv Neurol 2009; 2: 163-80.
103. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84.
104. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of AD amyloid-beta peptides. Nature 2003; 423: 435-9.
105. Sivaprakasam P, Xie A, Doerksen RJ. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition, 2D-QSAR for 3-anilino-4-phenylmaleimides. Bioorg Med Chem 2006; 14: 8210-8.
106. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313-7.
107. Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007; 31: 1046-63.
108. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol 2010; 127(1): 26-31.
109. Moreira PI, Santos MS, Seica R, Oliveira CR. Brain mitochondrial dysfunction as a link between AD and diabetes. J Neurol Sci 2007; 257: 206-14.